No Data
Express News | Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Equity Requirement
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3
Talphera's Promising Prospects: Buy Rating Affirmed Amidst Strategic Advancements in Anticoagulant Development
US Manufacturing Index Rises To 43, Highest Since 2020
H.C. Wainwright Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $6
Optimistic Buy Rating for Talphera Driven by Promising NEPHRO CRRT Study Progress and Niyad's Potential
No Data
